Bevacizumab in the treatment of NSCLC: patient selection and perspectives
Russo, Alessia E; Priolo, Domenico; Antonelli, Giovanna; Libra, Massimo; McCubrey, James A; Ferraù, Francesco
Non-small-cell lung cancer (NSCLC) represents about 85% of all lung cancers, and more than half of NSCLCs are diagnosed at an advanced stage. Chemotherapy has reached a plateau in the overall survival curve of about 10 months. Therefore, in last decade novel targeted approaches have been developed to extend survival of these patients, including antiangiogenic treatment. Vascular endothelial growth factor (VEGF) signaling pathway plays a dominant role in stimulating angiogenesis, which is the main process promoting tumor growth and metastasis. Bevacizumab (bev; Avastin®) is a recombinant humanized monoclonal antibody that neutralizes VEGF’s biologic activity through a steric blocking of its binding with VEGF receptor. Currently, bev is the only antiangiogenic agent approved for the first-line treatment of advanced or recurrent nonsquamous NSCLC in “bev-eligible” patients. The ineligibility to receive bev is related to its toxicity. In the pivotal trials of bev in NSCLC, fatal bleeding events including pulmonary hemorrhage were observed with rates higher in the chemotherapy-plus-bev group. Therefore, in order to reduce the incidence of severe pulmonary hemorrhage, numerous exclusion criteria have been characteristically applied for bev such as central tumor localization or tumor cavitation, use of anticoagulant therapy, presence of brain metastases, age of patients (elderly). Subsequent studies designed to evaluate the safety of bev have demonstrated that this agent is safe and well tolerated even in those patients subpopulations excluded from pivotal trials. This review outlines the current state-of-the-art on bev use in advanced NSCLC. It also describes patient selection and future perspectives on this antiangiogenic agent.
Russo, Alessia E, & Priolo, Domenico, & Antonelli, Giovanna, & Libra, Massimo, & McCubrey, James A, & Ferraù, Francesco. (December 2017). Bevacizumab in the treatment of NSCLC: patient selection and perspectives. Lung Cancer: Targets and Therapy, (259-269. Retrieved from http://hdl.handle.net/10342/8041
Russo, Alessia E, and Priolo, Domenico, and Antonelli, Giovanna, and Libra, Massimo, and McCubrey, James A, and Ferraù, Francesco. "Bevacizumab in the treatment of NSCLC: patient selection and perspectives". Lung Cancer: Targets and Therapy. . (259-269.), December 2017. March 04, 2021. http://hdl.handle.net/10342/8041.
Russo, Alessia E and Priolo, Domenico and Antonelli, Giovanna and Libra, Massimo and McCubrey, James A and Ferraù, Francesco, "Bevacizumab in the treatment of NSCLC: patient selection and perspectives," Lung Cancer: Targets and Therapy 8, no. (December 2017), http://hdl.handle.net/10342/8041 (accessed March 04, 2021).
Russo, Alessia E, Priolo, Domenico, Antonelli, Giovanna, Libra, Massimo, McCubrey, James A, Ferraù, Francesco. Bevacizumab in the treatment of NSCLC: patient selection and perspectives. Lung Cancer: Targets and Therapy. December 2017; 8() 259-269. http://hdl.handle.net/10342/8041. Accessed March 04, 2021.